fda shortage semaglutide injection resolved feb 21 2025 As of February 21, 2025, the updated its drug list, marking the shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A Semaglutide shortage ends as FDA

It helps produce healthy red blood cells, supports the nervous system and brain function, and boosts immune system health

Every plan includes nutrition and habit support to help you eat in a way that protects energy and muscle, even when appetite is lower

In March 2024 , the FDA approved Wegovy for another purpose: to reduce the risk of cardiovascular death, heart attack, or stroke in adults with existing heart disease and either obesity or overweight

What this means is that Semaglutide prompts your body to release insulin, which in turn, lowers your glucose (blood sugar) levels

STEP UP Phase 3b Trial Results: Semaglutide 7.2 mg in Adults with Obesity